PCVX vs PGEN

Vaxcyte, Inc. vs Precigen, Inc. — Valuation Comparison 2026

PCVX

Biotechnology
Vaxcyte, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$51.06
Last close
Models
10/13
Active
VS

PGEN

Biotechnology
Precigen, Inc.
Quality
4.3
out of 10
Value Trap
34
LOW
Price
$4.51
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType PCVX Fair ValuePCVX Upside PGEN Fair ValuePGEN Upside
Bayesian DCF Intrinsic $16.06 -68.6% $1.09 -75.8%
Earnings Power Value Intrinsic $27.17 -54.3%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $15.19 -70.3% $0.40 -91.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PCVX vs PGEN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PCVX vs PGEN — Which Stock Is More Undervalued?

PCVX scores higher with a 5.1/10 quality rating vs PGEN's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vaxcyte, Inc. (PCVX) and Precigen, Inc. (PGEN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PCVX currently trades at $51.06 with a QOC of 5.1/10, while PGEN trades at $4.51 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).